Permeon Biologics is pioneering a breakthrough class of intracellular biologics that target a broad spectrum of previously undruggable targets. Leveraging its Intraphilin™ Technology Platform exclusively licensed from Harvard University, the company’s next-generation approach is being developed to unlock the full therapeutic potential of current blockbuster technologies for human biologics. The Intraphilin™ Technology Platform enables protein-based therapeutics to act inside cells to treat disease, opening access to more than 1,500 intracellular targets that are deemed undruggable by existing technologies.

Noubar Afeyan and Doug Cole are on the Board of Directors.